Search
Archive

What to Watch in Healthcare in 2017

11 JAN 2017

The fate of the Affordable Care Act is shaping up to be the hottest healthcare issue publicly in 2017, but investors are watching drug pricing trends and M&A activity just as closely, says Goldman Sachs Research’s Jami Rubin. She explains why we’re likely to see a pickup in deals in a constrained pricing environment. 

 

In 2016 the level of M&A was actually lower than we thought it would be. We do expect a pretty significant pickup in 2017.

- Jami Rubin

Jami Rubin
Business Unit Leader, Healthcare Research Group, Goldman Sachs Research